SEC Form 4 · accession 0001415889-19-000110
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Ward
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Jan 30, 2019
Accepted (ET)
Jan 31, 2019 · 7:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2,F1 | $11.53 | Jan 30, 2019 | A | 226,000 | A | — | Jan 30, 2029 | Common Stock | 226,000 | 226,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter.
- F2The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan.